MassBio Newest Members

Autism Speaks, Inc.

Wed, 01 May 2013 12:00:00 EDT

Autism Speaks is the world's leading autism science and advocacy organization. We are dedicated to funding research into the causes, prevention, treatments and a cure for autism, increasing awareness of autism spectrum disorders, and advocating for the needs of individuals with autism and their families. Autism Speaks was founded in 2005 by Bob and Suzanne Wright, grandparents of a child with autism. Their long-time friend Bernie Marcus donated $25 million to help financially launch the organization. Since then, we have committed approximately $200 million to scientific research studies, training fellowships and international science initiatives.

Cellay Inc

Wed, 01 May 2013 12:00:00 EDT

Cellay is a FDA registered, cGMP compliant manufacturer of synthetic oligonucleotide probes used for oncology and hematology.

Charles River Labs

Wed, 01 May 2013 12:00:00 EDT

For more than 60 years, Charles River has provided tailored research models and laboratory animal support services, as well as preclinical and clinical support services, to help our global partners accelerate their research and drug development efforts. Our offerings span the entire drug development process, from discovery through market approval, forming a seamless partnership throughout the process.

Fish & Richardson PC

Wed, 01 May 2013 12:00:00 EDT

Fish & Richardson PC is one the largest intellectual property law firms in the U.S. We help biotechnology companies identify, create and protect intellectual property, including patents, trademarks and trade secrets. The firm's clients include large and small companies, universities, hospitals, individuals and investment firms. We also counsel clients on technology transfer matters and regulatory issues that govern biotechnology products both in the U.S. and abroad. Our patent prosecution work encompasses all biotechnology-related disciplines, including complex genetic engineering, immunology, neurology, virology, cell and transplantation biology, gene therapy, vaccines, gene regulation, transgenic animals and plants, and peptide analog design and synthesis.

We are skilled in interference proceedings and appeals at the Patent and Tradmeark Office. We have extensive experience litigating disputes involving biotechnology intellectual property rights. The firm's expertise covers intellectual property transactions, including licensing, development agreements, joint venture agreements, and technology transfer agreements.

Intellimedix

Wed, 01 May 2013 12:00:00 EDT

Intellimedix develops and applies novel technologies and approaches to accelerate the discovery of new treatments for neurological diseases. Its current focus is finding cures for Dravet Syndrome and other types of epilepsy.

Sotio, LLC

Wed, 01 May 2013 12:00:00 EDT

SOTIO is a biotechnology company that is developing the next generation Active Cellular Immunotherapy (ACI), based on activated dendritic cells for the treatment of cancer and autoimmune diseases. Our ACI products are the result of cutting-edge scientific thinking in the field of immunotherapy. SOTIO’s proprietary technology – Active Cellular Immunotherapy Multiple Antigen Presentation (ACI-MAP) – is being used in combination with other treatments in a synergistic way to induce a disease-specific immune response and to control disease progression. Efficient subcutaneous dosing allows for out-patient administration. Clinical trials are currently being conducted using our ACI product in ovarian and prostate cancer including our global phase 3 study combining ACI and first line chemotherapy - VIABLE. The company is also undertaking early-stage research focused on the use of an ACI in lung cancer. SOTIO continues to develop new therapies to address unmet medical needs and has an active presence in the United States, Europe, Russia, and China.

Xenetic Biosciences

Wed, 01 May 2013 12:00:00 EDT

Xenetic Biosciences focuses on developing next generation therapeutics for Orphan Diseases. We have three patented platform technologies available for the development of therapies, PolyXen, ImuXen and Oncohist. PolyXen Technology PolyXen is Xenetic Biosciences patented polysialyation technology platform for therapeutic compounds. Polysialyation is the attachment of defined lengths of the biopolymer polysialic acid (PSA) to a therapeutic compound. Various sizes of polysialic acid from 10 KDa to 70 KDa can be differentially attached to almost any therapeutic compound. This allows significant modification of the therapeutic compound’s physical, pharmacokinetic and pharmacodynamic properties. These modifications can include alterations in proteolytic degradation, thermal stability, biological half-life, immunological profile, therapeutic profile and formulation requirements. Polysialyation is all natural and is biodegradable to sialic acid. PolyXen is a next generation alternative to PEGylation for the delivery of therapeutic compounds. Xenetic Biosciences has clinical programs using the PolyXen technology for the treatment of anemia and cystic fibrosis. There are pre-clinical programs in progress using growth hormone, oxyntomodulin, insulin and blood factors. ImuXen Technology ImuXen is Xenetic Biosciences patented liposomal technology platform for the creation of new vaccines and the improvement of existing vaccines. It enables the simultaneous delivery of multiple potential antigens. Two or more proteins, peptides, DNA regions or polysaccharides are combined into a single liposomal vesicle. This allows the delivery of all the antigens to the same antigen presenting cell for processing at the same time. Proof of concept pre-clinical studies have shown a stronger and faster antibody response compared to adjuvant controls or singularly administered liposomal controls. Dependent on the antigens used, multiple vaccines can be delivered with a single injection, there can be a reduction in the number of doses required and a reduction observed side effects. Xenetic Biosciences has a clinical program using the ImuXen technology for multiple sclerosis. There are pre-clinical programs in progress for HIV and Alzheimer’s disease. OncoHist Clinical Program OncoHist is Xenetic Biosciences’ patented, recombinant form of human Histone H 1.3. This is a novel form, N-bis-met-histone H 1.3, of the molecule. It has demonstrated a significant anti-proliferative effect against a variety of over 60 cancer cells in vitro. It appears to have a novel mechanism of action that is currently part of a joint research effort with Dana Farber Cancer Institute. A phase 1 clinical trial against relapsed or refractory AML was successfully completed in Germany. OncoHist was shown to be well tolerated up to at least 628 mg/m2 with no significant safety concerns. No treated patients developed auto-antibodies against OncoHist. It is now in Phase 1 clinical trials in Russia in combination with cytarbine against primary refractory or relapsed acute myeloid leukaemia.

Brown University Continuing Education

Mon, 01 Apr 2013 12:00:00 EDT

Cogent Consulting, Inc.

Mon, 01 Apr 2013 12:00:00 EDT

Cogent Consulting is a healthcare strategy consulting company focused on identifying, quantifying, and capturing hidden growth opportunities for clients in the biopharma industry.

CoStim Pharmaceuticals

Mon, 01 Apr 2013 12:00:00 EDT

A cancer immunotherapy biotech company with a comprehensive portfolio of antibody drugs targeting immunological checkpoint control.

CryoXtract Instruments

Mon, 01 Apr 2013 12:00:00 EDT

Developer of automated product solutions for accessing/re-accessing all frozen biosamples while preserving the cryogenic state of the specimens.

Cydan Development Inc.

Mon, 01 Apr 2013 12:00:00 EDT

Cydan is an orphan drug accelerator that identifies and de-risks compounds with therapeutic and commercial potential. Our rigorous process generates data to support a development path and new company formation. Cydan’s experienced and globally networked team brings strong relationships with academia and patient advocacy, deep expertise in drug development, and a track record of successful product commercialization.

Jubilant Clinsys, Inc.

Mon, 01 Apr 2013 12:00:00 EDT

Jubilant Clinsys Inc. is a scientifically focused contract research organization that provides pharmaceutical, biotechnology and medical device companies with a full range of services in support of Phase I – IV drug and device development. The company is a subsidiary of Jubilant Life Sciences and a fully integrated partner with Jubilant Biosys and Jubilant Chemsys. Founded in 1992, the company operates globally at offices in Bedminster, New Jersey, USA; Raleigh, North Carolina, USA; Ottawa, Ontario; Canada, Noida and Bangalore, India and Dusseldorf, Germany. Jubilant Clinsys Inc. offers a full range of clinical research services including: Bioanalytical Services Biostatistics Clinical Informatics Clinical Laboratory Clinical Operations Clinical Pharmacology/Pathology Data Management/EDC Drug Safety Medical Affairs Medical Writing Pharmacovigilance Project Management Quality Assurance Regulatory Services

Lathrop & Gage LLP

Mon, 01 Apr 2013 12:00:00 EDT

A full-service law firm, Lathrop & Gage LLP has more than 320 attorneys in 11 offices nationwide – from Los Angeles to New York. Lathrop & Gage’s Boston office is positioned in the city’s downtown core. The Boston team provides sophisticated intellectual property services, particularly in the biotechnology, genetic engineering and life sciences fields. Our attorneys hold advanced scientific degrees and are among Chambers USA’s “Leading Lawyers” for Massachusetts IP.

VitaThreads, LLC

Mon, 01 Apr 2013 12:00:00 EDT

VitaThreads, LLC develops innovative fibrin-based bioresorbable devices that allow intuitive, targeted delivery of cell therapies for orthopedic, cardiac and other large-market applications.

X-Rx Discovery, Inc.

Mon, 01 Apr 2013 12:00:00 EDT

X-Rx Discovery specializes in bench to IND development of therapies for oncological, immunological and metabolic diseases. The company leverages its expertise in medicinal chemistry, assay development and preclinical POC to rapidly advance high value programs. X-Rx maintains a critical focus on therapeutic differentiation, developing unique profiles and prosecuting targets once thought to be intractable. This unique combination of skills and attributes drives corporate strategy, and has positioned the company for long-term growth and success.

ATR, LLC

Fri, 01 Mar 2013 12:00:00 EDT

We are a translational biomedical research company assisting clients in a smooth and timely transition from academic research into preclinical development by generating necessary data, information and documentation of biologic drug candidates for immunology-based disorders.

Bio-Concept Laboratories

Fri, 01 Mar 2013 12:00:00 EDT

BioConcept Laboratories, Inc. is a full-service FDA registered product development laboratory located North of Boston in Derry, New Hampshire. A portion of the facility is used for chemical, biochemical, and microbiological functions. The remainder is dedicated to an aseptic fill suite for the customized manufacture of sterile clinical and toxicological products. We offer quality service with the communication and flexibility that is vital for a successful collaboration. Our service is customized according to your needs. It is our mandate to compile a complete product profile leading to a timely and successful launch of your product.

Enterprise Lithuania

Fri, 01 Mar 2013 12:00:00 EDT

ENTERPRISE LITHUANIA (EL) is a public organization owned by the Ministry of Economy of the Republic of Lithuania. EL is a well known institution responsible for promoting Lithuanian producers exports well as supporting small and mid-sized businesses. Enterprise Lithuania helps to develop relations between Lithuanian and International business communities by: • Providing foreign businesses with the information of Lithuanian companies, goods and services best fitting their needs. • Helping foreign businesses to arrange partnerships with Lithuanian enterprises. • Organizing incoming/outgoing trade missions and contact fairs. • Planning and implementing international business promotion projects. Enterprise Lithuania has a network of 30 representatives worldwide, located in key markets to help establish the international business partnerships. Life Sciences Sector in Lithuania is regarded as one of the most advanced in Central and Eastern Europe, demonstrating 22% annual growth within the biotechnology and pharmaceutical research and production sector, and over 80% of the production being exported. With the pool of 18 000 researchers and specialists and over 100 companies operating in the life sciences area, the country is on the fast track of becoming one of the top high tech innovation centers in Europe. Enterprise Lithuania was the main organizer of the first and the biggest of its kind Life Sciences Baltics forum in Baltic. More than 720 participants from over 30 countries were introduced with the opportunities in the region. Next event is planned in 2014 (www.lsb2014.com). Please contact us or visit www.enterpriselithuania.com for more information.

Mispro Biotech Services

Fri, 01 Mar 2013 12:00:00 EDT

Mispro Biotech Services, a leading contract-service company, was established in 2003 to provide high quality support services in the early pre-clinical phase of therapeutic product development. Our mission is to provide high quality in-vivo support to the bio-pharmaceutical industry. Mispro offers a wide range of services including multi-user vivarium space, remote husbandry services and remote facility management. We look forward to partnering with you on your in vivo study needs. It is our commitment to provide you with the highest quality support.

Pathogenetix, Inc

Fri, 01 Mar 2013 12:00:00 EDT

PathoGenetix, Inc. is developing an automated system for rapid bacterial strain typing in a broad range of complex sample types. The company’s proprietary technology, called Genome Sequence Scanning (GSS), extracts and tags genomic DNA directly from complex biological samples, without the need for cultured isolates or primer design. No PCR or other amplification technique is necessary. GSS uses both the DNA fragment length and optical tags to create a genomic fingerprint, similar to a genomic barcode, which is recorded and compared to a database for strain identification. An initial result is available within five hours, and up to 48 samples can be processed in 24 hours.

Portugal Trade and Investment Agency, Aicep Portugal Global

Fri, 01 Mar 2013 12:00:00 EDT

Aicep Portugal Global is a Trade and Investment Agency opperating under the aegis of the Ministry of Foreign Affairs of Portugal. Our main mission is to promote exports of Portuguese quality goods and services and identify potential investors in Portugal. We are particularly active in the field of Biotechnology, Pharmaceutical and Medical devices.

Wise Construction Corp.

Fri, 01 Mar 2013 12:00:00 EDT

Wise Construction is one of the area’s most respected mid-sized construction firms. Our business is built on long-standing relationships with clients who value our commitment to service, excellence and flexibility. Our success is based on a clear understanding of each client's need and expectations. Wise Construction has provided exceptional service to clients in the Healthcare, Biotechnology, Higher Education and Corporate sectors throughout the Boston/Cambridge area. Wise Construction provides preconstruction, construction management and general contracting services, specializing in renovations in occupied spaces and in highly sensitive environments. Known for our hands-on approach and attention to detail, our firm is consistently chosen. We excel in terms of initiative, resourcefulness and sheer willingless to integrate with our clients and their projects. This focus on our people is central to our business philosophy and fundamental to our success.

Bayesian Ventures

Fri, 01 Feb 2013 12:00:00 EDT

Bridging the gap between world-class researchers and the life sciences community to transform human health.

Boston Healthcare Associates

Fri, 01 Feb 2013 12:00:00 EDT

Boston Healthcare helps emerging and established companies gain a competitive advantage in an increasingly complex health care marketplace. We provide reimbursement, market access, business development, and market analytics services to drug, device, and diagnostic clients worldwide. Boston Healthcare’s unique approach combines strategic consulting with a deep understanding of the business development and reimbursement environments to give clients a real-world edge in assessing, creating, and capturing growth opportunities.

Elsevier Business Intelligence

Fri, 01 Feb 2013 12:00:00 EDT

Elsevier Business Intelligence, a global leader in the field of healthcare industry information, provides business intelligence on regulatory, business and reimbursement issues that are vital to the healthcare industry. Through a range of products including publications, conferences, e-learning, databases and reports, Elsevier Business Intelligence places biopharma and medical device professionals, and those who focus on these industries, at the forefront of knowledge, by providing the perfect combination of news and information together with penetrating insight and analysis.

Forest Laboratories, Inc.

Fri, 01 Feb 2013 12:00:00 EDT

Forest Laboratories' (NYSE: FRX) longstanding global partnerships and track record developing and marketing pharmaceutical products in the United States have yielded its well-established central nervous system and cardiovascular franchises and innovations in anti-infective, respiratory, gastrointestinal and pain management medicine. Forest’s pipeline, the most robust in its history, includes product candidates in all stages of development across a wide range of therapeutic areas. The Company is headquartered in New York, NY. To learn more, visit www.FRX.com.

H4B Back Bay

Fri, 01 Feb 2013 12:00:00 EDT

H4B Back Bay is a full-service health care communications company based in the heart of Boston. Employing a fully unified, digital-at-the-core business model, H4B Back Bay is designed to flexibly meet the unique commercialization needs of the Cambridge/Boston biotechnology corridor. Our team’s expertise spans critical therapeutic areas, including medical devices, orphan drugs, and emerging oncologics. Our tightly integrated team of scientific, medical, and creative professionals is passionate about one thing – the opportunity to make your brand a reality so that, together, we can help more patients.

OnDeckBiotech

Fri, 01 Feb 2013 12:00:00 EDT

Sarepta Therapeutics

Fri, 01 Feb 2013 12:00:00 EDT

Sarepta Therapeutics is focused on developing first-in-class RNA-based therapeutics to improve and save the lives of people affected by serious and life-threatening rare and infectious diseases. The Company's diverse pipeline includes its lead program eteplirsen, for Duchenne muscular dystrophy, as well as potential treatments for some of the world's most lethal infectious diseases. Sarepta aims to build a leading, independent biotech company dedicated to translating its RNA-based science into transformational therapeutics for patients who face significant unmet medical needs. For more information, please visit us at www.sareptatherapeutics.com.